98651-66-2

Basic information

• Product Name: Ulobetasol
• Synonyms: Ulobetasol [inn];Unii-9p6159hm7t;(6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
• CAS NO: 98651-66-2
• Molecular Formula: C₂₂H₂₇ClF₂O₄
• Molecular Weight: 428.9
• Product Categories: Steroids
• Mol File: 98651-66-2.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• Stability: Hygroscopic
• CAS DataBase Reference: Ulobetasol(CAS DataBase Reference)
• NIST Chemistry Reference: Ulobetasol(98651-66-2)
• EPA Substance Registry System: Ulobetasol(98651-66-2)

Safety Data

• Hazardous Substances Data: 98651-66-2(Hazardous Substances Data)

Usage

Description

Ulobetasol, also known as Halobetasol, is a potent corticosteroid and anti-inflammatory drug. It is primarily used in dermatological treatments to manage various skin conditions, including different forms of psoriasis. Its anti-inflammatory and immunosuppressive properties make it an effective pharmaceutical agent for skin-related issues.

Uses

Used in Dermatological Applications:
Ulobetasol is used as a topical corticosteroid for treating various dermatological conditions. It is particularly effective in managing different forms of psoriasis, a chronic skin disorder characterized by red, scaly patches on the skin. The anti-inflammatory and immunosuppressive properties of Ulobetasol help reduce inflammation, itching, and scaling associated with psoriasis, providing relief and improving the overall appearance of the affected skin.
In addition to psoriasis, Ulobetasol may also be used to treat other skin conditions such as eczema, dermatitis, and contact dermatitis. Its potent anti-inflammatory action helps alleviate symptoms and promote healing in these conditions as well. However, it is essential to follow the guidance of a healthcare professional when using Ulobetasol to ensure safe and effective treatment.

Upstream product

• 84509-92-2 6α,9α-difluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione, 17-propionate 21-mesylate 

Relevant articles and documents

A PROCESS FOR PREPARING A CRYSTALLINE FORM OF HALOBETASOL PROPIONATE

The present invention provides a process for preparing a crystalline form of halobetasol propionate, comprising the step of crystallizing halobetasol propionate from absolute ethanol or a mixture of ethanol and water, wherein the crystalline form of halobetasol propionate is characterized by an x-ray powder diffraction pattern having peaks at 10.0, 11.6, 12.9, 13.4, 14.5, 16.4, 17.6, and 23.5 + 0.2 degrees 2θ.